Johnson & Johnson announced sales of $16.5 billion for the second quarter of 2012, a decrease of 0.7% as compared to the second quarter of 2011. Operational results increased 3.5%, and the negative impact of currency was 4.2%. Domestic sales decreased 1.2% while international sales decreased 0.4%, reflecting operational growth of 7.1% and a negative currency impact of 7.5%. Net earnings and diluted earnings per share for the second quarter of 2012 were $1.4 billion and $0.50, respectively, and the company adjusted its earnings guidance for full-year 2012 to $5.00–5.07 per share.
“Our talented associates around the world are building a strong foundation for sustainable growth through meaningful innovations and an expanding global footprint. Our pharmaceutical pipeline continued its strong momentum this quarter with the submission of several new drug applications, as well as strong growth from several recently launched products that meet critical patient needs,” said J&J CEO Alex Gorsky.
The company's worldwide consumer division's sales of $3.6 billion for the second quarter represented a decrease of 4.6% versus the prior year consisting of an operational increase of 0.6% and a negative impact from currency of 5.2%. Domestic sales decreased 1.9%, and international sales decreased 6%, which reflected an operational increase of 2% and a negative currency impact of 8%.
Positive contributors to operational results were international sales of oral care products, Neutrogena skin care products and international baby care products.
More information on this financial report, including stats and figures on J&J’s worldwide pharmaceutical and medical device divisions, is available here.